Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects.

about

Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects.

Item

http://www.wikidata.org/entity/Q35880178

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Focal treatment of spasticity ...... evaluation of adverse effects.

@ast

Focal treatment of spasticity ...... evaluation of adverse effects.

@en

type

Item

label

Focal treatment of spasticity ...... evaluation of adverse effects.

@ast

Focal treatment of spasticity ...... evaluation of adverse effects.

@en

prefLabel

Focal treatment of spasticity ...... evaluation of adverse effects.

@ast

Focal treatment of spasticity ...... evaluation of adverse effects.

@en

P1476

Focal treatment of spasticity ...... evaluation of adverse effects.

@en

P2093

Ana Paula Tedesco

http://www.w3.org/2001/XMLSchema#string

Juliana Saccol Martins

http://www.w3.org/2001/XMLSchema#string

Renata D'Agostini Nicolini-Panisson

http://www.w3.org/2001/XMLSchema#string

P2860

Multilevel botulinum toxin type a as a treatment for spasticity in children with cerebral palsy: a retrospective study.

Safety considerations in the use of botulinum toxins in children with cerebral palsy.

Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.

Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases.

Early communication about an ongoing safety review Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B).

Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.

Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement.

[Iatrogenic botulism: a complication to be taken into account in the treatment of child spasticity].

Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.

Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy.

P304

359-363

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.RBOE.2014.04.022

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262879589

http://www.w3.org/2001/XMLSchema#string

P698

26229827

http://www.w3.org/2001/XMLSchema#string

P932

4511629

http://www.w3.org/2001/XMLSchema#string